Modification of ChPL (chitosan protein–lipid) nanoparticles for in vitro release of rifampicin (RIF)

During recent years, the implication of nanoparticles (NPs) as drug delivery systems has gained much scientific attention. As drugs do not deliver themselves, a nanoparticle can act by optimizing drug delivery in the right place, at the right time and at the right dosage. In previous years, this res...

Full description

Bibliographic Details
Main Authors: Poopak Farnia, Jalaledin Ghanavi, Saeed Mollaei, Afshin Bahrami, Ali Akbar Velayati
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2015-01-01
Series:International Journal of Mycobacteriology
Subjects:
RIF
Online Access:http://www.ijmyco.org/article.asp?issn=2212-5531;year=2015;volume=4;issue=5;spage=16;epage=16;aulast=Farnia;type=0
id doaj-3daf240441124df89a683836172ae621
record_format Article
spelling doaj-3daf240441124df89a683836172ae6212020-11-25T01:08:27ZengWolters Kluwer Medknow PublicationsInternational Journal of Mycobacteriology2212-55312212-554X2015-01-0145161610.1016/j.ijmyco.2014.11.038Modification of ChPL (chitosan protein–lipid) nanoparticles for in vitro release of rifampicin (RIF)Poopak FarniaJalaledin GhanaviSaeed MollaeiAfshin BahramiAli Akbar VelayatiDuring recent years, the implication of nanoparticles (NPs) as drug delivery systems has gained much scientific attention. As drugs do not deliver themselves, a nanoparticle can act by optimizing drug delivery in the right place, at the right time and at the right dosage. In previous years, this research successfully developed and evaluated the ChPL-NPs nanoparticles (chitosan protein–lipid) [US patent pending 20140370500]. In the present investigation, rifampicin (RIF) ChPL-NPs nanoparticles were designed and developed. Consequently, the in vitro release of RIF ChPL-NPs nanoparticles was investigated. Material and Methods: Briefly, chitosan powder (90 KD and 90% degree of deacetylation) was dissolved (1% acetic-acid) and mixed with gelatin (3%). Then, the lipid and rifampin in ether was precipitated by rotary vacuum evaporator. Under high speed homogenizer (12,000rpm), both solutions (chitosan–gelatin & rifampin–lipid) were mixed [US patent pending 20140370500]. The obtained RIF ChPL-NPs were put into a dialysis bag with cut-off 14 KD in phosphate buffer solution (pH=7.4). The release of RIF was obtained by reverse phase HPLC using C18 (250 × 4.6 mm, 5 μm) column. The mobile phase consisted of 50:50 v/v acetonitrile and 10 mm potassium dihydrogen phosphate (pH=3.2) and flow rate 1 ml/min. The column temp was maintained at 25 °C with UV detection at 335nm. Results and conclusions: The average size of RIF ChPL-NPs was about 50–250nm. The release of RIF from the dialysis bag started after 30 min which was 2400ng/ml; after 16 h the release of RIF was 15,000ng/ml; and at 40 h the concentration reached to 19,600ng/ml. Therefore, these results showed a slow release of RIF from ChPL-NPs. Basically, the intensity of the surface charges in nanoparticle is important as it determines their interaction with bioactive compound. In RIF ChPL-NPs, lipid had negative charges, whereas chitosan and gelatin had positive charges. The electrostatic interaction between oppositely charged ions would ultimately cause an effective system drug delivery. RIF ChPL-NPs is not only suitable for intravenous administration, but it can be used as an inhalation aerosol, because this nanoparticle has a capacity to adhere to mucosal surfaces and transiently open the tight junction.http://www.ijmyco.org/article.asp?issn=2212-5531;year=2015;volume=4;issue=5;spage=16;epage=16;aulast=Farnia;type=0ChPL-NPsNanoparticlesRIFAntimycobacterial activity
collection DOAJ
language English
format Article
sources DOAJ
author Poopak Farnia
Jalaledin Ghanavi
Saeed Mollaei
Afshin Bahrami
Ali Akbar Velayati
spellingShingle Poopak Farnia
Jalaledin Ghanavi
Saeed Mollaei
Afshin Bahrami
Ali Akbar Velayati
Modification of ChPL (chitosan protein–lipid) nanoparticles for in vitro release of rifampicin (RIF)
International Journal of Mycobacteriology
ChPL-NPs
Nanoparticles
RIF
Antimycobacterial activity
author_facet Poopak Farnia
Jalaledin Ghanavi
Saeed Mollaei
Afshin Bahrami
Ali Akbar Velayati
author_sort Poopak Farnia
title Modification of ChPL (chitosan protein–lipid) nanoparticles for in vitro release of rifampicin (RIF)
title_short Modification of ChPL (chitosan protein–lipid) nanoparticles for in vitro release of rifampicin (RIF)
title_full Modification of ChPL (chitosan protein–lipid) nanoparticles for in vitro release of rifampicin (RIF)
title_fullStr Modification of ChPL (chitosan protein–lipid) nanoparticles for in vitro release of rifampicin (RIF)
title_full_unstemmed Modification of ChPL (chitosan protein–lipid) nanoparticles for in vitro release of rifampicin (RIF)
title_sort modification of chpl (chitosan protein–lipid) nanoparticles for in vitro release of rifampicin (rif)
publisher Wolters Kluwer Medknow Publications
series International Journal of Mycobacteriology
issn 2212-5531
2212-554X
publishDate 2015-01-01
description During recent years, the implication of nanoparticles (NPs) as drug delivery systems has gained much scientific attention. As drugs do not deliver themselves, a nanoparticle can act by optimizing drug delivery in the right place, at the right time and at the right dosage. In previous years, this research successfully developed and evaluated the ChPL-NPs nanoparticles (chitosan protein–lipid) [US patent pending 20140370500]. In the present investigation, rifampicin (RIF) ChPL-NPs nanoparticles were designed and developed. Consequently, the in vitro release of RIF ChPL-NPs nanoparticles was investigated. Material and Methods: Briefly, chitosan powder (90 KD and 90% degree of deacetylation) was dissolved (1% acetic-acid) and mixed with gelatin (3%). Then, the lipid and rifampin in ether was precipitated by rotary vacuum evaporator. Under high speed homogenizer (12,000rpm), both solutions (chitosan–gelatin & rifampin–lipid) were mixed [US patent pending 20140370500]. The obtained RIF ChPL-NPs were put into a dialysis bag with cut-off 14 KD in phosphate buffer solution (pH=7.4). The release of RIF was obtained by reverse phase HPLC using C18 (250 × 4.6 mm, 5 μm) column. The mobile phase consisted of 50:50 v/v acetonitrile and 10 mm potassium dihydrogen phosphate (pH=3.2) and flow rate 1 ml/min. The column temp was maintained at 25 °C with UV detection at 335nm. Results and conclusions: The average size of RIF ChPL-NPs was about 50–250nm. The release of RIF from the dialysis bag started after 30 min which was 2400ng/ml; after 16 h the release of RIF was 15,000ng/ml; and at 40 h the concentration reached to 19,600ng/ml. Therefore, these results showed a slow release of RIF from ChPL-NPs. Basically, the intensity of the surface charges in nanoparticle is important as it determines their interaction with bioactive compound. In RIF ChPL-NPs, lipid had negative charges, whereas chitosan and gelatin had positive charges. The electrostatic interaction between oppositely charged ions would ultimately cause an effective system drug delivery. RIF ChPL-NPs is not only suitable for intravenous administration, but it can be used as an inhalation aerosol, because this nanoparticle has a capacity to adhere to mucosal surfaces and transiently open the tight junction.
topic ChPL-NPs
Nanoparticles
RIF
Antimycobacterial activity
url http://www.ijmyco.org/article.asp?issn=2212-5531;year=2015;volume=4;issue=5;spage=16;epage=16;aulast=Farnia;type=0
work_keys_str_mv AT poopakfarnia modificationofchplchitosanproteinlipidnanoparticlesforinvitroreleaseofrifampicinrif
AT jalaledinghanavi modificationofchplchitosanproteinlipidnanoparticlesforinvitroreleaseofrifampicinrif
AT saeedmollaei modificationofchplchitosanproteinlipidnanoparticlesforinvitroreleaseofrifampicinrif
AT afshinbahrami modificationofchplchitosanproteinlipidnanoparticlesforinvitroreleaseofrifampicinrif
AT aliakbarvelayati modificationofchplchitosanproteinlipidnanoparticlesforinvitroreleaseofrifampicinrif
_version_ 1725182579272843264